0000000000452850

AUTHOR

Rosa Coll

showing 3 related works from this author

Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable res…

2021

Programa para el Tratamiento de Hemopatias Malignas (PETHEMA) Group (Spanish Society of Hematology, SEHH).

OncologyMalep13)/TCF3-PBX1Neoplasm ResidualOncogene Proteins FusionCytogenetic alterationsmedicine.medical_treatmentDiseaseTranslocation Genetichemic and lymphatic diseasesAntineoplastic Combined Chemotherapy Protocolst(1;19)(q23;p13)/TCF3-PBX1Cumulative incidenceCitogenètica humanaNeoplasm MetastasisLeucèmia limfoblàstica - TractamentHuman cytogeneticsLeukemiaAcute lymphoblastic leukaemiaRemission InductionLeucèmiaDisease ManagementHematologyMiddle AgedPrognosisHaematopoiesismedicine.anatomical_structureTreatment OutcomeChromosomes Human Pair 1TCF3:Other subheadings::Other subheadings::/therapy [Other subheadings]FemaleStem cell:Neoplasms::Neoplasms by Histologic Type::Leukemia::Leukemia Lymphoid::Precursor Cell Lymphoblastic Leukemia-Lymphoma::Precursor B-Cell Lymphoblastic Leukemia-Lymphoma [DISEASES]Adultmedicine.medical_specialtyPronòstic mèdicAdolescentQuimioteràpia combinadaYoung AdultInternal medicinePrecursor B-Cell Lymphoblastic Leukemia-LymphomamedicineAdultsHumansB cell19)(q23Neoplasm Staging:neoplasias::neoplasias por tipo histológico::leucemia::leucemia linfoide::leucemia-linfoma linfoblástico de células precursoras::leucemia-linfoma linfoblástico de células B precursoras [ENFERMEDADES]business.industryacute lymphoblastic leukaemia adults cytogenetic alterations prognosis t(1:Otros calificadores::Otros calificadores::/terapia [Otros calificadores]ImmunotherapyChromosome BandingTransplantationt(1Avaluació de resultats (Assistència sanitària)businessChromosomes Human Pair 19British journal of haematologyReferences
researchProduct

Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable resi…

2020

In the European LeukemiaNet favourable risk category, allogeneic haematopoietic stem cell transplantation (alloSCT) is not indicated in first complete remission for patients with acute myeloid leukaemia (AML) with NPM1 mutations (ELNfav NPM1 AML), although a proportion of these patients will relapse. Given the prognostic importance of measurable residual disease (MRD), CETLAM-12 considered a pre-emptive intervention in patients with molecular failure (MF). We analyzed 110 ELNfav NPM1 AML patients achieving complete remission (CR) after induction chemotherapy. Two-year cumulative incidence of relapse (CIR), overall survival (OS) and leukaemia-free survival (LFS) were 17%, 81 center dot 5% an…

OncologyAdultMalemedicine.medical_specialtyNPM1Neoplasm ResidualAdolescentDiseasestem cell transplantationDisease-Free Survival03 medical and health sciencesEuropean LeukemiaNet0302 clinical medicinehemic and lymphatic diseasesInternal medicinemedicineHumansacute myeloid leukaemiamolecular analysisCumulative incidenceAgedbusiness.industryInduction chemotherapyMyeloid leukemiaNuclear ProteinsHematologyInduction ChemotherapyMiddle AgedNeoplasm ProteinsTransplantationEuropeSurvival RateHaematopoiesisLeukemia Myeloid Acute030220 oncology & carcinogenesisleukaemiaMutationFemalebusinessNucleophosmin030215 immunologyBritish journal of haematologyReferences
researchProduct

Favorable Outcome in Patients with Acute Myeloblastic Leukemia (AML) with NPM1 Mutation Who Present an Inadequate Clearance or Relapse of Minimal/Mea…

2018

Abstract Introduction Patients diagnosed with AML with NPM1mutation (NPM1mut AML) included in the European LeukemiaNet favorable genetic risk category (ELNfav, i.e., without FLT3-ITD or with a low allelic burden FLT3-ITD comutation [FLT3-ITD/FLT3wt <0.5; FLT3-ITDLOW]) do not benefit from an allogeneic stem cell transplantation (alloSCT) in first complete remission (CR1). However, a significant proportion of these patients fail to frontline chemotherapy and require salvage therapy. Persistence or detection of MRD after post-CR treatment is associated with a high relapse risk and worse prognosis. With this background, the cooperative group CETLAM proposed an early therapeutic intervention …

Oncologymedicine.medical_specialtyAcute myeloblastic leukemiabusiness.industrymedicine.medical_treatmentImmunologySalvage therapyCell BiologyHematologyDiseasemedicine.diseaseDebulkingBiochemistryChemotherapy regimenLeukemiaInternal medicinemedicineCytarabinebusinessNeoadjuvant therapymedicine.drugBlood
researchProduct